Page 2,737«..1020..2,7362,7372,7382,739..2,7502,760..»

Neil Riordan PhD – Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments – Video

Posted: June 7, 2012 at 11:18 pm

06-06-2012 13:09 Mesenchymal stem cell homing to tissue damage, umbilical cord stem cells historically used for anti-aging, mesenchymal stem cells role in immune system modulation, inflammation reduction and stimulating tissue regeneration, donor stem cell safety and testing, the role of HLA matching in donated umbilical cord-derived stem cells, umbilical cord blood safety data and historical use in blood transfusions, allogeneic stem cell persistence in human mothers. Treatment information at More information on Dr. Riordan at

See more here:
Neil Riordan PhD - Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments - Video

Posted in Stem Cell Videos | Comments Off on Neil Riordan PhD – Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments – Video

Skin Cells Turned Into Brain Cells

Posted: June 7, 2012 at 11:18 pm

A team of scientists has discovered what could be a novel source for researching and potentially treating Alzheimer's disease and other conditions involving the destruction of brain cells.

Researchers at the University of California San Francisco-affiliated Gladstone Institutes converted skin cells from mice and humans into brain stem cells with the use of a protein called Sox2. Using only this protein to transform the skin cells into neuron stem cells is unusual. Normally, the conversion process is much more complex.

Neuron stem cells are cells that can be changed into the nerve cells and the cells that support them in the brain. The neuronal stem cells formed in this study are unique because they were prepared in a way the prevented them from becoming tumors, which is what often happens as stem cells differentiate, explained David Teplow, professor of neurology and director of the Easton Center for Alzheimer's Disease Research at UCLA. Teplow was not involved in the study, but is familiar with this type of research.

These immature brain stem cells then developed into different types of functional brain cells, which were eventually able to be integrated into mouse brains.

Jonathan Selig/Getty Images

The idea that these cells can become fully functioning brain tissue is significant, the authors explained, because by becoming part of the brain, the cells can replace the cells killed off by the disease process.

These cells also offer a potential way to learn about the mechanisms behind neurodegenerative disorders as well as lead to research into new drugs, explained Dr. Yadong Huang, a study co-author and associate investigator at the Gladstone Institute of Neurological Disease.

"The next step is, we are trying to get these skin cells from patients with this disease so we can reprogram and convert the diseased cells into these neuron stem cells and develop those into neurons in culture," he said.

After that, researchers can study how these diseases develop based on what's observed in culture dishes.

"It's really hard to get neurons from human brains for research, and now, we can generate them," Huang said. "Secondly, we can do some drug screening. If we have patient-specific neurons in culture, we can test some or develop some drugs to see how they work on these neurons."

Read more here:
Skin Cells Turned Into Brain Cells

Posted in Stem Cell Videos | Comments Off on Skin Cells Turned Into Brain Cells

Bio-Matrix Scientific Group's Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual …

Posted: June 7, 2012 at 11:18 pm

SAN DIEGO, CA--(Marketwire -06/07/12)- Bio-Matrix Scientific Group, Inc. (BMSN) (BMSN) announced today that its wholly owned subsidiary Regen BioPharma, Inc. has executed an exclusive option agreement which grants Regen BioPharma an option to license Patent #6,821,513 which patents methods of stimulating blood production in patients with deficient stem cells. The patent, as well as data licensed with the patent, covers methods of stimulating the bone marrow to generate new blood cells. The patent and option agreement are disclosed in the Company's most recent 8K filed with the US Securities and Exchange Commission on June 6, 2012.

"The technology has broad applicability to help cancer patients recover faster following chemotherapy, as well as for recipients of bone marrow and cord blood transplants. Currently, new blood cell production is stimulated by expensive drugs such as Neupogen and Neulasta which replicate the body's growth factors but can cause side effects and rely upon the diminished recuperative powers of an immune compromised patient," stated J. Christopher Mizer, President of Regen BioPharma.

David Koos, Chairman & CEO of Bio-Matrix Scientific Group, added, "We are excited to get this therapy into the clinic. Based on peer-reviewed published animal data, it has the potential to restore immune function faster and more effectively than the existing standard of care."

The licensed technology covers the use of a naturally-occurring cell type for stimulation of bone marrow stem cells. By utilizing cells as opposed to drugs, Regen BioPharma believes it possesses a substantial advantage to existing approaches in terms of safety and economics of production. Currently the market for growth factors that stimulate blood making stem cells is more than $4.84 billion per year (www.wikinvest.com/stock/Amgen).

About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:Bio-Matrix Scientific Group, Inc. (BMSN) (BMSN) is a biotechnology company focused on the development of regenerative medicine therapies and tools. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.

Through Its wholly owned subsidiary, Regen BioPharma, it is the Company's goal to develop translational medicine platforms for the rapid commercialization of stem cell therapies. The Company is looking to use these translational medicine platforms to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the Company's goal of increased quality of life.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Follow this link:
Bio-Matrix Scientific Group's Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual ...

Posted in Stem Cell Treatments | Comments Off on Bio-Matrix Scientific Group's Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual …

Type of stem cell may contribute to heart disease

Posted: June 7, 2012 at 11:18 pm

UC Berkeley scientists have discovered a type of stem cell that appears to lie dormant in blood vessel walls for decades before waking up and causing the arterial hardening and clogging that are associated with deadly strokes and heart attacks.

The findings, published Wednesday in the journal Nature Communications, go against the prevailing theory on the cause of heart disease - that the smooth muscle cells that line blood vessels become damaged over time and are triggered to proliferate. Those smooth muscle cells were thought to build up like scar tissue and cause the blood vessels to become narrow or brittle.

The new theory suggests that the smooth muscle cells found in the blood vessel walls aren't to blame, but rather a small cluster of stem cells is. It's those stem cells that proliferate and cause damage, and they should be the target of drug therapies to treat, and potentially cure, heart disease, the UC Berkeley scientists say.

"We call them sleeping beauty or sleeping evil cells, because they don't do anything when they're dormant. The stem cells stay quiescent for decades before they start to grow and they make the blood vessels harden," said senior author Song Li, a bioengineering professor at UC Berkeley and a researcher at the Berkeley Stem Cell Center.

"These stem cells are probably less than 5 percent of the cells in the blood vessel when they're dormant," Li said. "But they can dominate. They can become the major cell."

Li and his team still believe that smooth muscle cells are to blame for much of the damage in the blood vessels. What's changed is where those cells come from.

Scientists have known for decades that the blood vessel damage associated with heart disease is caused by a buildup of smooth muscle cells. Those clumps of cells cause the blood vessel to become dangerously narrow, hindering the flow of blood, or they become brittle clots that break off and block vessels entirely.

When the blood flow is slowed or stopped completely, it can cause strokes or heart attacks, depending on the location of the blockage. Strokes and heart attacks are among the most common causes of death in the United States.

The stem cells, which Li and his team have named multipotent vascular stem cells, remained undiscovered because so few of them exist when they're dormant. It didn't help that after they become activated, they look very similar to the smooth muscle cells that scientists have long thought were the culprit in heart disease.

The prevailing theory has been that damage to the blood vessel caused the smooth muscle cells in the vessel walls to "de-differentiate," or revert to an earlier stage of development that allows them to reproduce and build the scar-like tissue. But there was no proof of it, Li and others noted.

More:
Type of stem cell may contribute to heart disease

Posted in Stem Cell Research | Comments Off on Type of stem cell may contribute to heart disease

Bio-Matrix Scientific Group's Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual …

Posted: June 7, 2012 at 10:19 pm

SAN DIEGO, CA--(Marketwire -06/07/12)- Bio-Matrix Scientific Group, Inc. (BMSN) (BMSN) announced today that its wholly owned subsidiary Regen BioPharma, Inc. has executed an exclusive option agreement which grants Regen BioPharma an option to license Patent #6,821,513 which patents methods of stimulating blood production in patients with deficient stem cells. The patent, as well as data licensed with the patent, covers methods of stimulating the bone marrow to generate new blood cells. The patent and option agreement are disclosed in the Company's most recent 8K filed with the US Securities and Exchange Commission on June 6, 2012.

"The technology has broad applicability to help cancer patients recover faster following chemotherapy, as well as for recipients of bone marrow and cord blood transplants. Currently, new blood cell production is stimulated by expensive drugs such as Neupogen and Neulasta which replicate the body's growth factors but can cause side effects and rely upon the diminished recuperative powers of an immune compromised patient," stated J. Christopher Mizer, President of Regen BioPharma.

David Koos, Chairman & CEO of Bio-Matrix Scientific Group, added, "We are excited to get this therapy into the clinic. Based on peer-reviewed published animal data, it has the potential to restore immune function faster and more effectively than the existing standard of care."

The licensed technology covers the use of a naturally-occurring cell type for stimulation of bone marrow stem cells. By utilizing cells as opposed to drugs, Regen BioPharma believes it possesses a substantial advantage to existing approaches in terms of safety and economics of production. Currently the market for growth factors that stimulate blood making stem cells is more than $4.84 billion per year (www.wikinvest.com/stock/Amgen).

About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:Bio-Matrix Scientific Group, Inc. (BMSN) (BMSN) is a biotechnology company focused on the development of regenerative medicine therapies and tools. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.

Through Its wholly owned subsidiary, Regen BioPharma, it is the Company's goal to develop translational medicine platforms for the rapid commercialization of stem cell therapies. The Company is looking to use these translational medicine platforms to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the Company's goal of increased quality of life.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Read more here:
Bio-Matrix Scientific Group's Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual ...

Posted in Cell Medicine | Comments Off on Bio-Matrix Scientific Group's Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual …

Neil Riordan PhD – Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments – Video

Posted: June 7, 2012 at 1:18 pm

06-06-2012 13:09 Mesenchymal stem cell homing to tissue damage, umbilical cord stem cells historically used for anti-aging, mesenchymal stem cells role in immune system modulation, inflammation reduction and stimulating tissue regeneration, donor stem cell safety and testing, the role of HLA matching in donated umbilical cord-derived stem cells, umbilical cord blood safety data and historical use in blood transfusions, allogeneic stem cell persistence in human mothers. Treatment information at More information on Dr. Riordan at

Go here to see the original:
Neil Riordan PhD - Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments - Video

Posted in Cell Therapy | Comments Off on Neil Riordan PhD – Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments – Video

Bio-Matrix Scientific Group’s Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual …

Posted: June 7, 2012 at 1:18 pm

SAN DIEGO, CA--(Marketwire -06/07/12)- Bio-Matrix Scientific Group, Inc. (BMSN) (BMSN) announced today that its wholly owned subsidiary Regen BioPharma, Inc. has executed an exclusive option agreement which grants Regen BioPharma an option to license Patent #6,821,513 which patents methods of stimulating blood production in patients with deficient stem cells. The patent, as well as data licensed with the patent, covers methods of stimulating the bone marrow to generate new blood cells. The patent and option agreement are disclosed in the Company's most recent 8K filed with the US Securities and Exchange Commission on June 6, 2012.

"The technology has broad applicability to help cancer patients recover faster following chemotherapy, as well as for recipients of bone marrow and cord blood transplants. Currently, new blood cell production is stimulated by expensive drugs such as Neupogen and Neulasta which replicate the body's growth factors but can cause side effects and rely upon the diminished recuperative powers of an immune compromised patient," stated J. Christopher Mizer, President of Regen BioPharma.

David Koos, Chairman & CEO of Bio-Matrix Scientific Group, added, "We are excited to get this therapy into the clinic. Based on peer-reviewed published animal data, it has the potential to restore immune function faster and more effectively than the existing standard of care."

The licensed technology covers the use of a naturally-occurring cell type for stimulation of bone marrow stem cells. By utilizing cells as opposed to drugs, Regen BioPharma believes it possesses a substantial advantage to existing approaches in terms of safety and economics of production. Currently the market for growth factors that stimulate blood making stem cells is more than $4.84 billion per year (www.wikinvest.com/stock/Amgen).

About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:Bio-Matrix Scientific Group, Inc. (BMSN) (BMSN) is a biotechnology company focused on the development of regenerative medicine therapies and tools. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.

Through Its wholly owned subsidiary, Regen BioPharma, it is the Company's goal to develop translational medicine platforms for the rapid commercialization of stem cell therapies. The Company is looking to use these translational medicine platforms to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the Company's goal of increased quality of life.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

See original here:
Bio-Matrix Scientific Group's Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual ...

Posted in Cell Medicine | Comments Off on Bio-Matrix Scientific Group’s Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual …

Treatment eases arthritis pain in dogs

Posted: June 7, 2012 at 1:17 pm

A local veterinary clinic recently added a cuttingedge treatment.

Dr. Tina Gemeinhardt, owner of Tsawwassen Animal Hospital, is excited to be offering stem cell therapy to animals suffering from arthritis and joint issues.

"I'm excited about trying to bring some relief to dogs that are living in pain," she said.

The therapy, which uses stem cells harvested from fat that is surgically removed from the dog, is, in most cases, able to offer relief from the pain and stiffness associated with

Gemeinhardt said once it's determined the therapy is the right course of treatment for an animal, body fat is surgically removed and sent to a lab in California where the stem cells are harvested. The harvested stem cells are then sent back to the vet clinic within 48 hours and injected into the joints in question.

Gemeinhardt, who added the treatment to the clinic's list of services earlier this year, said it's not quite clear exactly how the stem cells work.

"Stem cells seem to inherently know what needs to be done in that area," she said.

The treatment is not a cure-all - the arthritis is still there but the symptoms are lessened - and it does not work instantly. The vet said most animals start to notice a difference in a month or so, and some might require follow up injections.

She said about 85 per cent of animals receiving stem cell therapy have had a beneficial response, while 15 per cent saw no response.

Beatrice, a seven-yearold chow chow, has seen remarkable results. Owner Rose McClelland said Beatrice had been having problems with arthritis in her hips for years and medication wasn't working any more.

Continued here:
Treatment eases arthritis pain in dogs

Posted in Cell Therapy | Comments Off on Treatment eases arthritis pain in dogs

Stem cells are identified as real culprit behind heart attacks after case of mistaken identity that could …

Posted: June 7, 2012 at 11:12 am

Scientists previously thought heart attacks and strokes were caused by smooth muscle cells Stem cells multiply and caused arteries to harden Heart attacks affect 90,000 and strokes 150,000 in Britain every year

By Emma Reynolds

PUBLISHED: 11:17 EST, 6 June 2012 | UPDATED: 11:17 EST, 6 June 2012

The real culprit behind heart attacks and strokes is stem cells, researchers have claimed in a landmark study that could revolutionise treatment.

Until now, scientists thought vascular health problems were triggered by smooth muscle cells.

Now a team from the University of California in Berkeley have found a previously unknown stem cell, which causes the arteries to harden when it multiplies.

Real hope: The cells can multiply and cause arteries to harden, blocking the blood's route to the heart or brain

The groundbreaking work is set to completely change how heart attacks and strokes are treated, dramatically cutting the number of deaths, according the study published today in the journal Nature Communications.

Heart attacks are the most common reason for people to need emergency treatment. Around 90,000 people in Britain have one each year - of whom around a third will die as a result.

More:
Stem cells are identified as real culprit behind heart attacks after case of mistaken identity that could ...

Posted in Stem Cell Videos | Comments Off on Stem cells are identified as real culprit behind heart attacks after case of mistaken identity that could …

Stem cells real culprit behind hardened arteries

Posted: June 7, 2012 at 11:12 am

BERKELEY One of the top suspects behind killer vascular diseases is the victim of mistaken identity, according to researchers from the University of California, Berkeley, who used genetic tracing to help hunt down the real culprit. The guilty party is not the smooth muscle cells within blood vessel walls, which for decades was thought to combine with cholesterol and fat that can clog arteries. Blocked vessels can eventually lead to heart attacks and strokes, which account for one in three deaths in the United States.

Instead, a previously unknown type of stem cell a multipotent vascular stem cell is to blame, and it should now be the focus in the search for new treatments, the scientists report in a new study appearing today (June 6) in the journal Nature Communications.

"For the first time, we are showing evidence that vascular diseases are actually a kind of stem cell disease," said principal investigator Song Li, professor of bioengineering and a researcher at the Berkeley Stem Cell Center. "This work should revolutionize therapies for vascular diseases because we now know that stem cells rather than smooth muscle cells are the correct therapeutic target."

The finding that a stem cell population contributes to artery-hardening diseases, such as atherosclerosis, provides a promising new direction for future research, the study authors said.

"This is groundbreaking and provocative work, as it challenges existing dogma," said Dr. Deepak Srivastava, who directs cardiovascular and stem cell research at the Gladstone Institutes in San Francisco, and who provided some of the mouse vascular tissues used by the researchers. "Targeting the vascular stem cells rather than the existing smooth muscle in the vessel wall might be much more effective in treating vascular disease."

It is generally accepted that the buildup of artery-blocking plaque stems from the body's immune response to vessel damage caused by low-density lipoproteins, the bad cholesterol many people try to eliminate from their diets. Such damage attracts legions of white blood cells and can spur the formation of fibrous scar tissue that accumulates within the vessel, narrowing the blood flow.

However, no experiments published have directly demonstrated this de-differentiation process, so Li and his research team remained skeptical. They turned to transgenic mice with a gene that caused their mature smooth muscle cells to glow green under a microscope.

In analyzing the cells from cross sections of the blood vessels, they found that more than 90 percent of the cells in the blood vessels were mature smooth muscle cells. They then isolated and cultured the cells taken from the middle layer of the mouse blood vessels.

After one month of cell expansion, the researchers saw a threefold increase in the size of the cell nucleus and the spreading area, along with an increase in stress fibers. Notably, none of the new, proliferating cells glowed green, which meant that their lineage could not be traced back to the mature smooth muscle cells originally isolated from the blood vessels.

"Not only was there a lack of green markers in the cell cultures, but we noticed that another type of cell isolated from the blood vessels exhibited progenitor traits for different types of tissue, not just smooth muscle cells," said Zhenyu Tang, co-lead author of the study and a Ph.D. student in the UC Berkeley-UCSF Graduate Program in Bioengineering.

Originally posted here:
Stem cells real culprit behind hardened arteries

Posted in Stem Cell Videos | Comments Off on Stem cells real culprit behind hardened arteries

Page 2,737«..1020..2,7362,7372,7382,739..2,7502,760..»